title: Photodynamic therapy-induced killing is enhanced in depigmented metastatic melanoma cells.
abstract: The resistance of pigmented human melanomas over their unpigmented counterparts to a number of therapies has suggested that the presence of intracellular melanin plays a role in rendering these cells less susceptible to cell death, probably through the ability of this pigment to act as an intracellular antioxidant, thus neutralizing chemotherapeutic-induced ROS (reactive oxygen species). PDT (photodynamic therapy) was recently suggested as an attractive, adjunctive therapy owing to its cellular specificity and limited side effects. In the present study, we propose that first depigmenting melanomas with a reversible TYR (tyrosinase) inhibitor such as PTU (phenylthiourea) increases their susceptibility to HYP-PDT (hypericin-mediated PDT). Pigmented [UCT Mel-1 (University of Cape Town melanoma cell line 1)] and unpigmented (A375) melanomas were first characterized with respect to their TYR activities and melanin quantities and then treated with a TYR inhibitor for 48 h. Cell viability assays after treatment with 3 μM HYP-PDT showed a significant increase in cell death in depigmented melanomas compared with untreated melanomas that returned to the level of untreated melanoma cells on removing the TYR inhibitor. The present study supports the hypothesis that combining the inhibition of melanogenesis with PDT should be explored as a valid therapeutic target for the management of advanced melanoma.
authors.affiliation: Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa.
authors.forename: Krishna V
authors.initials: KV
authors.lastname: Sharma
authors.forename: Natalie
authors.initials: N
authors.lastname: Bowers
authors.forename: Lester M
authors.initials: LM
authors.lastname: Davids
mesh_terms: D000873:Anthracenes; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary; D014442:Monophenol Monooxygenase / Q000037:antagonists & inhibitors; D010569:Perylene / Q000031:analogs & derivatives / Q000494:pharmacology; D010670:Phenylthiourea / Q000494:pharmacology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000494:pharmacology*; D010858:Pigmentation / Q000187:drug effects; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D000873:Anthracenes; D017319:Photosensitizing Agents; D017382:Reactive Oxygen Species; D010569:Perylene; D010670:Phenylthiourea; C004965:hypericin; D014442:Monophenol Monooxygenase